Pharmacogenetics, drug-metabolizing enzymes, and clinical practice.
نویسندگان
چکیده
The application of pharmacogenetics holds great promise for individualized therapy. However, it has little clinical reality at present, despite many claims. The main problem is that the evidence base supporting genetic testing before therapy is weak. The pharmacology of the drugs subject to inherited variability in metabolism is often complex. Few have simple or single pathways of elimination. Some have active metabolites or enantiomers with different activities and pathways of elimination. Drug dosing is likely to be influenced only if the aggregate molar activity of all active moieties at the site of action is predictably affected by genotype or phenotype. Variation in drug concentration must be significant enough to provide "signal" over and above normal variation, and there must be a genuine concentration-effect relationship. The therapeutic index of the drug will also influence test utility. After considering all of these factors, the benefits of prospective testing need to be weighed against the costs and against other endpoints of effect. It is not surprising that few drugs satisfy these requirements. Drugs (and enzymes) for which there is a reasonable evidence base supporting genotyping or phenotyping include suxamethonium/mivacurium (butyrylcholinesterase), and azathioprine/6-mercaptopurine (thiopurine methyltransferase). Drugs for which there is a potential case for prospective testing include warfarin (CYP2C9), perhexiline (CYP2D6), and perhaps the proton pump inhibitors (CYP2C19). No other drugs have an evidence base that is sufficient to justify prospective testing at present, although some warrant further evaluation. In this review we summarize the current evidence base for pharmacogenetics in relation to drug-metabolizing enzymes.
منابع مشابه
Challenges and Promises of Pharmacogenetics in Cancer Therapeutics
Genetic constitution represents an important cause for individual variations in the response and tolerance to drug treatment. Th ese variations are due to the germline mutations in genes that encode for drug-metabolizing enzymes, transporters, cellular targets and signaling pathways. Th e identifi cation of genetic variations that predict for drug response is an important step towards the trans...
متن کاملI-33: Pharmacogenetics of Reproductive Medicine
Adverse drug reactions (ADRs) are a major problem in drug therapy and drug development. Inter-individual genetic differences can have significant roles in determining an individual’s susceptibility to ADRs. The rapid development of techniques in the area of genome analysis has put the scientific community in a power position and facilitated identification of new pharmacogenomic biomarkers that ...
متن کاملPharmacogenetics; mini review
If it were not for the great variability among individuals medicine might as well be a science and not an art.” The thoughts of Sir William Osler in 1892 reflect the view of medicine over the past 100 years.1 Modern pharmacogenetics has its origins in the 1950s with a series of discoveries.2 The genetic basis underlying variations in drug response has become evident with the introduction of mod...
متن کاملPharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
Pharmacogenetics is the study of the linkage between an individual's genotype and that individual's ability to metabolize a foreign compound. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Phenotypes exhibiting poor and ultraextensive metabolism resul...
متن کاملPharmacogenetics of Chronic Pain and Its Treatment
This paper reviews the impact of genetic variability of drug metabolizing enzymes, transporters, receptors, and pathways involved in chronic pain perception on the efficacy and safety of analgesics and other drugs used for chronic pain treatment. Several candidate genes have been identified in the literature, while there is usually only limited clinical evidence substantiating for the penetrati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Pharmacological reviews
دوره 58 3 شماره
صفحات -
تاریخ انتشار 2006